First Manhattan’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

First Manhattan’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-33	Closed	–	–	1755
2021 Q4	$0	Hold	33	–	–	﹤0.01%	1762
2021 Q3	$0	Hold	33	–	–	﹤0.01%	1742
2021 Q2	$0	Hold	33	–	–	﹤0.01%	1679
2021 Q1	$0	Hold	33	–	–	﹤0.01%	1602
2020 Q4	$0	Hold	33	–	–	﹤0.01%	1461
2020 Q3	$0	Hold	33	–	–	﹤0.01%	1527
2020 Q2	$0	Hold	33	–	–	﹤0.01%	1537
2020 Q1	$0	Hold	33	–	–	﹤0.01%	1519
2019 Q4	$0	Hold	33	–	–	﹤0.01%	1429
2019 Q3	$0	Hold	33	–	–	﹤0.01%	1462
2019 Q2	$0	Hold	33	–	–	﹤0.01%	1493
2019 Q1	$0	Hold	33	–	–	﹤0.01%	1512
2018 Q4	$0	Sell	33 -3	-8%	-$5	﹤0.01%	1505
2018 Q3	$0	Hold	36	–	–	﹤0.01%	1484
2018 Q2	$0	Hold	36	–	–	﹤0.01%	1476
2018 Q1	$0	Hold	36	–	–	﹤0.01%	1537
2017 Q4	$0	Hold	36	–	–	﹤0.01%	1575
2017 Q3	$0	Hold	36	–	–	﹤0.01%	1557
2017 Q2	$0	Hold	36	–	–	﹤0.01%	1529
2017 Q1	$0	Sell	36 -1	-3%	-$5	﹤0.01%	1509
2016 Q4	$0	Hold	37	–	–	﹤0.01%	1514
2016 Q3	$0	Hold	37	–	–	﹤0.01%	1535
2016 Q2	$0	Hold	37	–	–	﹤0.01%	1590
2016 Q1	$0	Hold	37	–	–	﹤0.01%	1526
2015 Q4	$0	Hold	37	–	–	﹤0.01%	1567
2015 Q3	$0	Hold	37	–	–	﹤0.01%	1552
2015 Q2	$0	Hold	37	–	–	﹤0.01%	1561
2015 Q1	$0	Hold	37	–	–	﹤0.01%	1586
2014 Q4	$0	Hold	37	–	–	﹤0.01%	1605
2014 Q3	$0	Hold	37	–	–	﹤0.01%	1535
2014 Q2	$1K	Hold	37	–	–	﹤0.01%	1399
2014 Q1	$1K	Hold	37	–	–	﹤0.01%	1390
2013 Q4	$0	Hold	37	–	–	﹤0.01%	1468
2013 Q3	$0	Hold	37	–	–	﹤0.01%	1458
2013 Q2	$0	Buy	+37	New	+$434	﹤0.01%	1412

Other funds holding CTIC

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

First Manhattan's CTIC Position: Q1 2022 in Review

First Manhattan sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2022, closing a stake of 33 shares.

First Manhattan first reported a position in CTIC in Q2 2013 and held it in 35 quarters. The position peaked at $1K in Q2 2014. 92 funds tracked by Wall St. Rank hold CTIC as of Q1 2022.

First Manhattan reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2022 after selling out during the quarter.
First Manhattan sold 33 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2022.
First Manhattan first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 35 quarters.
First Manhattan's CTI BioPharma Corp. (DE) Common Stock position peaked at $1K in Q2 2014.
92 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2022.

Based on First Manhattan's 13F filing for Q1 2022, filed 16 May 2022.